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Gut microbiota plays critical physiological roles in the energy extraction and in the control of local or systemic immunity. Gut 
microbiota and its disturbance also appear to be involved in the pathogenesis of diverse diseases including metabolic disorders, 
gastrointestinal diseases, cancer, etc. In the metabolic point of view, gut microbiota can modulate lipid accumulation, lipopoly-
saccharide content and the production of short-chain fatty acids that affect food intake, inflammatory tone, or insulin signaling. 
Several strategies have been developed to change gut microbiota such as prebiotics, probiotics, certain antidiabetic drugs or fecal 
microbiota transplantation, which have diverse effects on body metabolism and on the development of metabolic disorders.  
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the field of diabetes and metabolism. Sulwon Award is named 
after an emeritus professor Eung Jin Kim, who founded Korean 
Diabetes Association. Prof. Myung-Shik Lee received the fifth 
Sulwon Award at 2014 International Conference on Diabetes 
and Metabolism, October 16-18, 2014 at Gyeonggido, Korea.
INTRODUCTION
The adult gut microbiota comprises 10 to 100 trillion microor-
ganisms, which is equivalent to ten times the number of our to-
tal somatic and germ cells [1]. Further, the collective genomes 
of gut microbiota (microbiome) contain 100- to 150-fold more 
genes than our own genome [2]. The gut microbiota has co-
evolved with humans and has shown profound effects on vari-
ous host responses. Recent findings have suggested that an al-
tered gut microbial composition is associated with metabolic 
diseases, including obesity, diabetes, or non-alcoholic fatty liver 
disease. These findings have indicated that the gut microbiota 
should be considered as an important factor to modulate host 
metabolism and metabolic disorders.
OBESITY-ASSOCIATED CHANGES IN THE 
COMPOSITION OF INTESTINAL MICROBIOTA
The gut microbiota plays an important role in the regulation of 
the host’s metabolism and the extraction of energy from ingest-
ed food. Gut microbiota have not only the beneficial functions 
for the host but also the pathophysiological interactions with 
the host, particularly in the case of obesity and related metabol-
ic disorders. Recent studies have shown that changes in the gut 
microbiota may be related in the pathogenesis of obesity and 
diabetes. For example, germ-free mice are protected from high 
fat diet (HFD)-induced obesity and metabolic dysfunction, in-
cluding glucose intolerance, which is due to derepression of 
fasting-induced adipose factor (Fiaf), an inhibitor of lipopro-
tein lipase (LPL) [1,3,4]. Additionally, the colonization of germ-
free animals with gut microbiota isolated from conventionally 
raised obese donors led to a significant increase in body fat 
content and insulin resistance in recipient mice [5,6]. Most 
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bacterial species in the mouse and human gut belong to the 
phyla Bacteroidetes and Firmicutes. Compared with their lean 
counterparts, leptin-deficient ob/ob mice showed a decrease in 
Bacteroidetes and a corresponding increase in Firmicutes [7]. 
Interestingly, studies with humans also have shown that gut 
microbiota composition differs between obese and lean sub-
jects [5,7]. Recently, two large metagenome-wide association 
studies reported that subjects with type 2 diabetes mellitus 
(T2DM) had a lower proportion of butyrate-producing Clos-
tridiales (Roseburia and Faecalibacterium prausnitzii) and 
greater proportions of Clostridiales that do not produce butyr-
ate, suggesting a protective role of butyrate-producing bacteria 
against T2DM [8,9].
 Currently, it is not known whether these changes in the in-
testinal microbiota composition are secondary to the altered 
gastrointestinal motility and small intestinal bacterial over-
growth that are often seen in T2DM. Nevertheless, selected in-
testinal bacterial strains may function in the clinic as early di-
agnostic markers to better identify obese subjects who might 
be prone to develop T2DM, and provide a novel therapeutic 
modality against obesity or T2DM.
MECHANISMS BY WHICH INTESTINAL 
MICROBIOTA ARE ASSOCIATED WITH 
OBESITY AND DIABETES
Short-chain fatty acids 
An essential role of gut microbiota is the fermentation of di-
etary polysaccharides that the host cannot otherwise digest. 
Dietary fibers constitute the indigestible portion of plant foods 
containing insoluble and soluble fibers. These soluble fibers are 
digested by enzymes derived from the gut microbiota into 
short-chain fatty acids (SCFAs). SCFAs (butyrate, acetate, and 
propionate) are absorbed in the intestines and used as energy 
by the host. In addition to their role as energy substrates, SC-
FAs function as regulators of food or energy intake [10] and 
inflammation [11]. It is well known that SCFAs are associated 
with increased satiety and reduced food intake [10]. SCFAs 
bind to G protein-coupled receptors, (GPCRs) such as GPR41 
and GPR43, which are expressed in the enteroendocrine cells 
[12]. This action leads to the secretion of certain peptide hor-
mones, such as peptide YY (PYY), that are released basolater-
ally into the systemic circulation, enabling a form of commu-
nication between the gut milieu and the host. Reduced food 
intake is, in part, due to the increases in the gut hormones, 
such as glucagon-like peptide (GLP)-1 and PYY [13] which 
decrease appetite and energy intake, and due to the decreased 
release of the gut peptide ghrelin, which increases food intake 
through effects on the hypothalamic and brainstem reward-re-
lated circuits (Fig. 1) [14]. SCFAs-mediated activation of GPR43 
resulted in suppression of insulin signaling in the adipose tissue 
Fig. 1. Gut microbiota regulation of host metabolism. Undi-
gested carbohydrates are fermented by gut microbiota into 
short-chain fatty acids (SCFAs), primarily acetate, propionate, 
and butyrate. SCFAs affect the host metabolism in several 
ways. SCFAs can signal through G protein-coupled receptor 
41 (GPR41) on enteroendocrine cells, inducing the secretion 
of peptide YY (PYY) which inhibits gut motility, increases in-
testinal transit rate, and reduces the harvest of energy from the 
diet. Engagement of GPR43 by SCFAs has been shown to trig-
ger the glucogon-like peptide 1 (GLP-1) to increase insulin 
sensitivity. Gut microbiota efficiently suppresses fasting-in-
duced adipose factor (Fiaf) expression in the ileum, which in-
hibits lipoprotein lipase (LPL) activity and fat storage in white 
adipose tissue. SCFAs-mediated activation of GPR43 results in 
suppression of insulin signaling in the adipose tissue and sub-
sequent prevention of fat accumulation. SCFAs also activate 
intestinal gluconeogenesis (IGN) via a gut-brain neural cir-
cuit, which can improve glucose metabolism and reduce food 
intake. VLDL, very low density lipoprotein; FFA, free fatty 
acid.
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subsequently preventing fat accumulation [15]. Recent study 
reported that dietary soluble fibers exert their antiobesity and 
antidiabetic effects via the induction of intestinal gluconeogen-
esis (IGN), which is contrary to the general idea that gluconeo-
genesis impairs glucose tolerance [16]. Butyrate activates IGN 
gene expression through a cAMP-dependent mechanism, while 
propionate, itself a substrate of IGN, activates IGN gene expres-
sion via a gut-brain neural circuit [16]. Glucose released by IGN 
is detected by a portal vein glucose sensor that signals to the 
brain through the peripheral nervous system, thus exerting 
beneficial effects on food intake and improving glucose toler-
ance (Fig. 1)[16,17]. 
Gut permeability and metabolic endotoxemia
Several recent studies have suggested that disruption of the gut 
barrier function and the gut microbiota-derived endotoxemia 
could contribute to the pathogenesis of obesity and T2DM 
[18,19]. A HFD dramatically increased gut permeability and 
reduced the expression of tight junction protein, such as zonula 
occludens-1 and occludin, in the intestinal epithelial cells of 
mice (Fig. 2) [20]. Disruption of the gut barrier in genetically 
or HFD-induced obese mice increased gut permeability, result-
ing in the leakage of lipopolysaccharide into the portal blood 
circulation (Fig. 2) [21-23]. Consistent with this concept, the 
modulation of the gut microbiota composition with antibiotics 
or prebiotics improved gut permeability, reduced metabolic 
endotoxemia, lowered inflammation, and alleviated glucose in-
tolerance [24].
INTESTINAL MICROBIOTA MODULATION 
AS NOVEL THERAPEUTIC STRATEGIES FOR 
OBESITY AND DIABETES
Prebiotics
Prebiotics are non-digestible but fermentable polysaccharides, 
such as inulin, fructo-, oligosaccharides, galato-oligosaccha-
rides, or lactulose. Foods artificially enriched with these fibers 
are defined as prebiotics, which promote SCFA production and 
the growth of beneficial bacteria, especially Bifidobacterium 
and Lactobacillus [25]. Studies in healthy humans and rodents 
have demonstrated that prebiotic consumption reduces hunger 
and enhances satiety [26]. As discussed above, this modulation 
of ingestive behavior is mediated, in part, by SCFA-induced 
changes in gut peptide secretion. Additionally, by promoting 
Bifidobacterium populations, prebiotics improve gut barrier 
function [27].
Probiotics
Probiotics are defined as live microorganisms that confer a ben-
eficial health effect on the host when administered in proper 
amounts. Some probiotic strains, especially those of the genera 
Lactobacillus and Bifidobacterium, have been shown to amelio-
rate obesity and metabolic disorders. The suggested mecha-
nisms include inhibition of the pathogen adhesion to gut mu-
cosa, stabilization of the microbial community, or improve-
ment of the mucosal integrity and barrier function [27-31]. The 
improvements of gut barrier function may reflect the actions of 
the SCFA products of bacterial fermentation. A recent study re-
Fig. 2. Effect of high fat diet (HFD) and metformin on gut mi-
crobiota and intestinal environment. A HFD induces gut mi-
crobial alteration, which increases gut permeability and re-
duces the expression of tight junction protein, such as zonula 
occludens (ZO)-1 and occludin, in the intestinal epithelial 
cells, results in the passage of lipopolysaccharide (LPS) into 
the portal blood circulation. The disruption of the gut barrier 
function and the gut microbiota-derived endotoxemia could 
contribute to the pathogenesis of obesity, insulin resistance, 
and type 2 diabetes mellitus (T2DM). Metformin is able to af-
fect the mouse microbiota and restored the decreased abun-
dance of Akkermansia muciniphila, a mucin-degrading G (–) 
anaerobes, in the gut of mice fed a HFD to that of mice fed 
normal chow diet. A. muciniphila had similar beneficial meta-
bolic effects to that of metformin administration. 
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ported the direct beneficial actions of Lactobacilli on the epithe-
lial cells and on the enteric nervous system regulating gut con-
tractility [32].
Drugs
A recent study showed that metformin, widely used for treat-
ment of T2DM, is able to slow aging in Caenorhabditis elegans 
by metabolically altering Escherichia coli with which it is cocul-
tured [33]. This effect was found to be due to the alteration of 
folate and the methionine metabolism of E. coli by metformin. 
Metformin decreased the methionine cycle and increased the 
levels of both S-adenosylmethionine (SAMe) and S-adenosyl-
homocystein. SAMe acts a co-repressor of methionine synthe-
sis genes and also inhibits the folate cycle, resulting in deceler-
ated aging in the worm [33].
 Metformin can also affect the intestinal microbiota of mam-
mals. We have demonstrated that metformin is able to affect the 
mouse microbiota and increase the abundance of Akkermansia 
muciniphila, a mucin-degrading G (–) anaerobes, in the gut of 
experimental mice fed a HFD (Fig. 2) [34]. We also observed 
that the administration of A. muciniphila had similar beneficial 
metabolic effects to that of metformin administration: (1) in-
creased the number of mucin-producing goblet cells was simi-
larly found after the administration of metformin or A. mu-
ciniphila; (2) diminished regulatory T (Treg) cell numbers and 
elevated interleukin 1β (IL-1β) or IL-6 mRNA expression in 
the visceral adipose tissue of mice fed a HFD were similarly re-
versed after the administration of metformin or A. muciniphila. 
Mucin has recently been shown to enhance delivery of tolero-
genic immunoregulatory signal to the intestinal epithelium by 
forming galectin-3-dectin-1-FcγRIIB complex besides its clas-
sical role as a physical barrier [35] This study therefore under-
scores that drugs, such as metformin, might exert therapeutic 
effects, at least in part by modulating the gut micriobiota.
Fecal microbiota transplantation
Recently, articles in the literature regarding fecal microbiota 
transplantation (FMT) have aroused strong interest. FMT is re-
ported to be a highly successful therapy for recurrent Clostridi-
um difficile infection [36]. These results also suggested a poten-
tial therapeutic effect of FMT in metabolic syndrome or T2DM. 
A recent study showed that FMT via a gastroduodenal tube 
from lean donors into obese subjects with metabolic syndrome 
induced a significant improvement of insulin sensitivity in the 
recipients [37]. FMT resulted in an increase of the microbial di-
versity and a 2.5-fold increase in the proportion of butyrate pro-
ducer Roseburia intestinalis after 6 weeks of treatment, whereas, 
fecal SCFA levels were decreased. Despite this first evidence that 
such as approach could be attractive, more information is need-
ed with larger, well-designed studies to prove whether such ap-
proaches are overall beneficial for patients with metabolic syn-
drome or T2DM.
CONCLUSIONS
Intestinal microbiota may play an important role in the patho-
genesis of T2DM by influencing body weight, proinflammato-
ry activity, and insulin resistance (Fig. 1). Future studies are re-
quired to increase our understanding of the complex interplay 
between intestinal microbiota and the host with T2DM and to 
enable the development of innovative and effective treatments 
for T2DM.
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